29 results about "Meticillin resistance" patented technology

Described herein is a synergistic combination comprising a quorum-sensing inhibitor and / or postbiotic metabolite and an antibiotic. Typically, the postbiotic metabolite comprises at least one peptide. Related compositions, uses, and methods are also described, including methods for resensitizing resistant bacteria to an antibiotic, and methods of treating antibiotic-resistant infections, such as methicillin-resistant Staphylococcus aureus (MRSA).

The application relates to the technical field of biological medicine, in particular to a compound with a conjugated structure containing an alpha, beta-unsaturated aldehyde and application thereof. The compound can covalently modify Sortase A enzyme of propionibacterium acnes through alpha, beta-unsaturated aldehyde, inhibit transpeptidation catalysis and adhesion of gram-positive bacteria (for example, methicillin-resistant staphylococcus aureus, streptococcus mutans and propionibacterium acnes), block anchoring of membrane proteins, inhibit growth of gram-positive bacteria or kill bacteria; conjugated groups with different electric effects and steric effects are screened to adjust the covalent modification efficiency of alpha, beta-unsaturated aldehyde and Sortase A enzyme, strengthen the activity of the compound in inhibiting Sortase A enzyme, thereby improve the antibacterial activity of the compound, and further make the compound with the conjugated structure containing the alpha, beta-unsaturated aldehyde in the application be applied to the fields of biological medicine and cosmetics as an antibacterial component.

The invention provides a multifunctional antibacterial nano particle. The antibacterial nano particle is a cross-linked product of a raw material composition comprising the following components (A) to (C): (A) a quinonoid conjugated organic molecule as shown in the following formula (I): # imgabs0 # (B) an amphiphilic aldehyde group-containing block copolymer; and, (C) L-arginine. The antibacterial nano particle disclosed by the invention has a synergistic effect on the basis of a principle of photo-thermal sterilization, photodynamic sterilization and gas sterilization, has good effects of resisting bacteria, eliminating bacterial biofilms and promoting wound recovery, and is particularly suitable for treating drug-resistant bacterium infection such as methicillin-resistant staphylococcus (MRSA) infection.

The invention discloses cycloastragenol derivatives with activity of resisting methicillin-resistant staphylococcus aureus and a preparation method of the cycloastragenol derivatives. According to the invention, cycloastragenol is used as a matrix, and is optimized by a chemical synthesis means to obtain a series of novel cycloastragenol derivatives. Experiments for resisting methicillin-resistant staphylococcus aureus prove that the series of compounds have good activity for resisting methicillin-resistant staphylococcus aureus, can be used as active ingredients of antibacterial drugs, and have relatively wide application in development of novel antibiotics.

Disclosed are compositions, methods and systems for detecting MRSA, for example MRSA nasal colonization. In certain embodiments, the methods use bacteriophage-based amplification of the signal in detection of bacteria and other microorganisms to detect MRSA. The methods for detecting MRSA may include preparing an assay comprising a selective agent and a cocktail comprising at least two different types of recombinant bacteriophages, incubating the sample in the assay, capturing an indicator protein product, and detecting an indicator protein product produced by the recombinant bacteriophage, wherein positive detection of the indicator protein product indicates that MRSA is present in the sample.

The invention relates to bifidobacterium longum NKU1-4 and application of the bifidobacterium longum NKU1-4 in inhibition of methicillin-resistant staphylococcus aureus drug resistance. The NKU1-4 belongs to bifidobacterium longum subspecies, has a preservation number of GDMCC No.64046, is derived from excrement of a breast-fed baby, and belongs to an acknowledged safe edible strain. The bifidobacterium longum NKU1-4 can generate an inhibition effect on methicillin-resistant staphylococcus aureus, cell-free supernate cultured by the bifidobacterium longum NKU1-4 can inhibit the growth of the methicillin-resistant staphylococcus aureus and also can inhibit the expression of drug-resistant genes of the methicillin-resistant staphylococcus aureus, and the bifidobacterium longum NKU1-4 can be effectively used for resisting the drug resistance of the methicillin-resistant staphylococcus aureus. Good medicinal values and application prospects are realized.

Cannabinoid analogs disclosed herein may exhibit antibacterial and anti-inflammatory properties. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) infections, as well as various disorders associated with chronic inflammation, such as arthritis. In some aspects, a pharmaceutical composition may be administered to an individual who has been exposed or is at risk of exposure to Bacillus anthracis or Bacillus anthracis spores.

A method of making a supplemented wound dressing including preparing a coffee extract with or without cardamom and supplementing the wound dressing with the coffee extract is provided. The coffee beans may be Khulani coffee beans and they may be green coffee beans, lightly roasted coffee beans, or medium roasted coffee beans. The supplemented wound dressing prepared according to this method is effective to inhibit bacterial growth, particularly growth of methicillin-resistant Staphylococcus aureus.

The present invention relates to a method for determining the methicillin resistance properties of a strain of Staphylococcus aureus present in a biological sample, comprising the following steps: a) incubation of the biological sample containing said strain of Staphylococcus aureus for at least 15 minutes, in the presence of a beta-lactam antibiotic selected from the following group: cefoxitin and 6-APA (6-aminopenicillanic acid), b) isolation of the bacteria present in said biological sample, c) lysis of the bacteria and hydrolysis of the bacterial proteins, in order to obtain a mixture of peptides, d) analysis of this mixture of peptides by targeted mass spectrometry, the detection of at least one peptide from the PBP2a protein (SEQ ID NO. 1) or PBP2c protein (SEQ ID NO. 2) during this analysis step being indicative of the methicillin resistance of the strain of Staphylococcus aureus present in said biological sample.

The application belongs to the technical field of antibacterial preparations, and particularly relates to the use of pamaquin or a salt thereof in resisting methicillin-resistant Staphylococcus aureus. Pamaquin or a salt thereof can effectively inhibit and kill methicillin-resistant Staphylococcus aureus in vitro, the effective inhibitory concentration of pamaquin or a salt thereof on methicillin-resistant Staphylococcus aureus is greater than or equal to 500 μg / mL, and the effective bactericidal concentration is greater than or equal to 1000 μg / mL; in vivo, pamaquin or a salt thereof can effectively eliminate methicillin-resistant Staphylococcus aureus in blood and / or viscera, so as to reduce the load of methicillin-resistant Staphylococcus aureus in blood and / or viscera.

The present invention provides the use of 5-fluoro-2'-deoxycytidine (CDP-3) in the preparation of antibacterial drugs. The present invention discovers for the first time that CDP-3 can inhibit the synthesis of bacterial phosphatidylglycerol by targeting bacterial phosphatidylglycerol phosphate synthase, and has antibacterial and broad-spectrum synergistic activities. Its MICs against Staphylococcus aureus and Streptococcus are 4 μg / mL and 8 μg / mL respectively, and the MIC 90 against methicillin-resistant Staphylococcus aureus is 8 μg / mL, and the MIC against hypervirulent Klebsiella pneumoniae is 16 μg / mL. In addition, CDP-3 can significantly enhance the antibacterial efficacy of antibiotics such as clindamycin, tilmicosin, tetracycline, florfenicol, gentamicin, chloramphenicol, rifampicin and ofloxacin against multi-drug resistant Gram-negative bacteria, and has broad-spectrum synergistic activity. Sub-inhibitory concentrations of CDP-3 can not only inhibit bacterial growth, but also reduce bacterial biofilm formation, and inhibit virulence and pathogenicity. CDP-3 not only increases the survival rate of Galleria mellonella infected with MRSA, but also shows excellent therapeutic efficacy against animal models infected with multi-drug resistant Gram-negative bacteria.

The invention belongs to the technical field of antibacterial preparations, and particularly relates to application of palmatine or salt thereof in resisting methicillin-resistant staphylococcus aureus. The palmatine or the salt thereof can effectively inhibit and kill methicillin-resistant staphylococcus aureus in vitro, the effective inhibitory concentration of the palmatine or the salt thereof on the methicillin-resistant staphylococcus aureus is greater than or equal to 500 mu g / mL, and the effective bactericidal concentration of the palmatine or the salt thereof on the methicillin-resistant staphylococcus aureus is greater than or equal to 1000 mu g / mL; the methicillin-resistant staphylococcus aureus in blood and / or visceral organs can be effectively removed in vivo, so that the load of the methicillin-resistant staphylococcus aureus in the blood and / or visceral organs is reduced.

The invention discloses a series of xanthoxylin ether derivatives containing pyridine structures as well as a preparation method and antibacterial application of the xanthoxylin ether derivatives. According to the series of compounds, a natural compound xanthoxylin is taken as a guide, structural optimization is carried out on a methoxy group of the natural compound xanthoxylin, and a sulfydryl pyridine quaternary ammonium salt fragment is introduced, so that a series of xanthoxylin ether derivatives containing pyridine structures are prepared, and the structural general formula of the xanthoxylin ether derivatives is shown as a formula (I). The series of compounds have high in-vivo and in-vitro antibacterial activity on Staphylococcus aureus ATCC 29213 and clinically separated methicillin-resistant Staphylococcus aureus (MRSA), and the antibacterial activity of the compounds is equivalent to that of a clinical first-line drug vancomycin. Through structural optimization, the water solubility and antibacterial activity of the xanthoxylin are enhanced, and the xanthoxylin has relatively low in-vivo and in-vitro toxicity and hemolytic activity and is not easy to generate drug resistance. Therefore, the xanthoxylin ether derivatives containing the pyridine structure have the potential of being further developed into novel antibacterial drugs. # imgabs0 #

The invention discloses a trypsin inhibitory peptide with antibacterial activity and application of the trypsin inhibitory peptide. Drug-resistant bacteria cause millions of infections in the world every year, and development of novel antibacterial agents becomes an important task. The invention discloses a bifunctional polypeptide with strong trypsin inhibitory activity and antibacterial activity. The peptide is also a novel derivative (BBI) of Borman-Burkholderia trypsin inhibitor polypeptide; the derivative peptide not only has strong bactericidal ability to two drug-resistant strains of Escherichia coli and methicillin-resistant staphylococcus, but also has excellent performance in safety evaluation of erythrocyte dissolution activity and anti-proliferative activity to human epithelial cuticle forming cells. Besides, the antibacterial activity of the novel bifunctional peptide is not obviously interfered under the conditions of salt ions, serum and trypsin, and the novel bifunctional peptide shows certain resistance to the salt ions, the serum and the trypsin. Therefore, the peptides have clinical development potential as novel clinical antibacterial preparations.

A bio-sensor device for the electrochemical detection of a bacterial pathogen, the device including a sample chamber and an electronic data module. The sample chamber includes passive sensing probes to detect pathogenic antigens in a sample containing the bacterial pathogen. The probes detect a reaction voltage corresponding to an antigen-antibody reaction occurring when the pathogenic antigens come into contact with an antibody specific for pathogenic antigens present in in the contents of the sample chamber and contacted by the electrical probes. The electronic data module detects and processes electrical signals detected by the conductive electrical probes corresponding to an amount of the antigen present in the sample, wherein the reaction voltage is detected at the time of the reaction.

The application belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide and application thereof. The antibacterial peptide is obtained by acetyl capping and amino capping modification of the amino acid sequence shown in SEQ ID NO. 1. The antibacterial peptide provided by the application has high inhibition activity on pathogenic bacteria Staphylococcus aureus, methicillin-resistant Staphylococcus aureus and methicillin- and gentamicin-resistant Staphylococcus aureus, and has good pH stability.

This composition for improving the drug sensitivity of an antibacterial drug to methicillin-resistant Staphylococcus aureus (MRSA) comprises at least one bacteriophage selected from the group consisting of the bacteriophage identified by accession number NITE BP-693 and the bacteriophage identified by accession number NITE BP-694.

The embodiment of the present application discloses a flavonoid compound and a preparation method and application thereof.The flavonoid compound has the following structural formula:8,2'-diisopentenyl quercetin-3-methyl ether and 8-isopentenyl kaempferol separated from an extract of Radix Scutellariae have good inhibitory effect on methicillin-resistant Staphylococcus, and provide a better scientific basis for clinical treatment of methicillin-resistant Staphylococcus infection, and development and utilization of active ingredients 8,2'-diisopentenyl quercetin-3-methyl ether and 8-isopentenyl kaempferol of Radix Scutellariae.

The invention discloses a staphylococcus warneri strain and application thereof, the staphylococcus warneri strain is classified and named as staphylococcus warneri, the strain number is OC4-19, the staphylococcus warneri strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.33795. The staphylococcus warneri strain is named as staphylococcus warneri. The staphylococcus warneri OC4-19 strain disclosed by the invention has a remarkable bacteriostatic effect on a plurality of clinically common gram-positive drug-resistant pathogenic bacteria, including community-acquired MRSA, hospital-acquired MRSA, animal-derived MRSA, methicillin-resistant staphylococcus epidermidis (MRSE), vancomycin-resistant enterococcus faecium (VRE) and the like; the broad-spectrum gram-positive pathogenic bacterium resisting activity of the OC4-19 strain provides a new direction for developing novel antibacterial drugs or therapies, especially the problem of increasingly serious antibiotic resistance nowadays.

The invention discloses a series of amphiphilic cnidium lactone-quaternary ammonium salt heterozygotes as well as a preparation method and antibacterial application thereof. According to the series of compounds, a natural compound cnidium lactone is taken as a lead, a hydrophilic quaternary ammonium salt fragment is introduced to a methoxy group through structure optimization, so that a series of amphiphilic cnidium lactone-quaternary ammonium salt heterozygotes are prepared, and the structural general formula of the amphiphilic cnidium lactone-quaternary ammonium salt heterozygotes is shown as a formula (I). The series of compounds have high in-vivo and in-vitro antibacterial activity on Staphylococcus aureus ATCC 29213 and clinically separated methicillin-resistant Staphylococcus aureus (MRSA), and the antibacterial activity of the compounds is equivalent to that of a clinical first-line drug vancomycin. Through structural optimization, the water solubility and antibacterial activity of the compound are enhanced, and the compound has relatively low in-vivo and in-vitro toxicity and hemolytic activity and is not easy to generate drug resistance. Therefore, the amphiphilic cnidium lactone-quaternary ammonium salt heterozygotes have the potential of being further developed into novel antibacterial drugs.

Multi-drug resistant (MDR) bacteria potentially pose a significant risk to people in the United States and all over the world; at the moment, the risk is the greatest where antibiotics are most commonly taken. The most notable MDR organisms are Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococcus faecium (VRE) and Carbapenem-resistant Pseudomonas aeruginosa. All three are associated with nosocomial infections. Embodiments of the present invention are directed to marine microorganism fractions and products for treating multi-drug resistant bacterial infections.

A method of making a supplemented wound dressing including preparing a coffee extract with or without cardamom and supplementing the wound dressing with the coffee extract is provided. The coffee beans may be Khulani coffee beans and they may be green coffee beans, lightly roasted coffee beans, or medium roasted coffee beans. The supplemented wound dressing prepared according to this method is effective to inhibit bacterial growth, particularly growth of methicillin-resistant Staphylococcus aureus.

The present invention provides a class of TB-double-bond-pyridinium derivatives and their preparation methods and applications. 4-bromoaniline, paraformaldehyde, DMF, three pyridine derivatives and iodomethane are selected as raw materials and synthesized through a multi-step reaction to obtain: #imgabs0# The three TB-double-bond-pyridinium derivatives have excellent photophysical properties, pH applicable range, viscosity response, AIE properties and good biocompatibility. The DCHA probe detected that all three products can produce ROS, and under the same conditions, the ROS production of 14 is higher. The DHR123 probe and EPR detected that all three compounds can produce superoxide anions. The results of antibacterial experiments showed that 14 exhibited excellent aPDT activity against Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (8μmol·L ‑1 The inhibition rates were 92% and 96% respectively. 14 had low dark toxicity but high phototoxicity to human bronchial epithelial cells, and both dark and phototoxicity were high to A459 cells. It also had a high safety factor SI, suggesting that it has the potential to be developed as a new anti-lung cancer drug.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide and application thereof. The antibacterial peptide provided by the invention is obtained by modifying an amino acid sequence as shown in SEQ ID NO.1 through acetyl end capping and amino end capping. The antibacterial peptide provided by the invention has efficient inhibitory activity on pathogenic bacteria staphylococcus aureus, methicillin-resistant staphylococcus aureus and methicillin-resistant and gentamicin-resistant staphylococcus aureus; the pH stability is good.

A method of making a supplemented wound dressing including preparing a coffee extract with or without cardamom and supplementing the wound dressing with the coffee extract is provided. The coffee beans may be Khulani coffee beans and they may be green coffee beans, lightly roasted coffee beans, or medium roasted coffee beans. The supplemented wound dressing prepared according to this method is effective to inhibit bacterial growth, particularly growth of methicillin-resistant Staphylococcus aureus.

The invention belongs to the technical field of biology, and discloses an antibacterial peptide and application thereof. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO.1, the molecular weight of the antibacterial peptide is 2265.89 Da, and the isoelectric point of the antibacterial peptide is 10.07. The antibacterial peptide has relatively strong antibacterial activity on staphylococcus aureus, especially methicillin-resistant staphylococcus aureus, and can effectively control infection of methicillin-resistant staphylococcus aureus; the compound has the advantages of good stability, high synthesis efficiency, low production cost and the like, and can be used for preparing medicines, feed additives or food preservatives for preventing diseases caused by methicillin-resistant staphylococcus aureus.

The present application provides a multifunctional antibacterial nanoparticle, which is a crosslinked product of a raw material composition comprising the following components (A) to (C): (A) a quinoid conjugated organic molecule represented by the following formula (I): (B) an amphiphilic aldehyde group-containing block copolymer; and, (C) L-arginine. The antibacterial nanoparticle of the present application eradicates bacteria based on the synergistic effect of the "photothermal sterilization-photodynamic sterilization-gas sterilization" principle, has good antibacterial, bacterial biofilm elimination and wound recovery promotion effects, and is particularly suitable for the treatment of drug-resistant bacteria infections such as methicillin-resistant Staphylococcus aureus (MRSA) infections.

The invention provides broad-spectrum salt ion tolerance staphylococcus aureus bacteriophage lyase and application, and belongs to the technical field of microorganisms. The lyase comprises an amino acid sequence shown as SEQ ID NO.2, or the lyase has at least 95% of homology with the amino acid sequence shown as SEQ ID NO.2 and has the same function as the amino acid sequence shown as SEQ ID NO.2. The staphylococcus aureus bacteriophage lyase provided by the invention has relatively good water solubility, salt ion and pH tolerance and temperature stability, is relatively wide in host spectrum, and can inhibit growth of methicillin-resistant and oxacillin-resistant staphylococcus aureus in chicken, clear biological membranes of the methicillin-resistant and oxacillin-resistant staphylococcus aureus, inhibit growth of the methicillin-resistant and oxacillin-resistant staphylococcus aureus, inhibit growth of the methicillin-resistant and oxacillin-resistant staphylococcus aureus and inhibit growth of the methicillin- no cytotoxicity exists.

A method of making a supplemented wound dressing including preparing a coffee extract with or without cardamom and supplementing the wound dressing with the coffee extract is provided. The coffee beans may be Khulani coffee beans and they may be green coffee beans, lightly roasted coffee beans, or medium roasted coffee beans. The supplemented wound dressing prepared according to this method is effective to inhibit bacterial growth, particularly growth of methicillin-resistant Staphylococcus aureus.